Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Roche’s High-End China Strategy

publication date: May 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Roche Holding AG will continue to implement its high-end pharma strategy in emerging markets, continuing to focus on the expensive, innovative drugs for which it is well known, rather than seeking to compete in the generic market. "Our strategy, in contrast to many of our peers, is to sell differentiated products with clear clinical benefits, [because they] are cost-effective and can sustain higher prices," said Pascal Soriot, COO of Roche's Pharmaceutical Division. More details...

Stock Symbol: (VX: ROG)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...